1. Neoadjuvant Imatinib in DFSP
SARC004
November 2008 update

2. SARC004: Pre-operative Imatinib in DFSP
Objectives
Determine effects of imatinib on phosphorylation of PDGFRB in DFSP
Correlate inhibition of PDGFRB with:
Plasma levels of imatinib
Inhibition of downstream kinases
Inhibition of tumor proliferation – Ki-67/MIB-1
Induction of apoptosis
Bank patient matched tissue for future study

3. DFSP: Pre-operative Treatment Plan
Pre-imatinib fresh tumor for molecular studies is required
Imatinib 400 mg bid for 10 to 14 days prior to planned surgical resection
Blood draw for imatinib plasma level within 24 hrs of surgery
Collect tumor for study at surgery
15 evaluable patients (viable matched tumor tissue/subject taking imatinib)

4. Accrual by participating SARC sites
MD Anderson
6 completed treatment; but 1 ineligible
University of Michigan
5 completed study,1 screen failure
University of Florida (closing)
1 completed study
Pennsylvania Oncology – Open
Moffitt
1 patient enrolled on 10/8/2008
13/15 enrolled – 1st patient enrolled 12/2006

5. SARC004: SAE Post-operative atypical chest pain
Post-operative wound infection requiring intravenous antibiotics